- Home
- PLCE vs ESLA Comparison
PLCE vs ESLA Comparison
Compare PLCE & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLCE | ESLA |
|---|---|---|
| Founded | 1969 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 60.9M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLCE | ESLA |
|---|---|---|
| Price | $3.36 | $1.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 514.2K | 162.9K |
| Earning Date | 04-10-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $0.78 |
| 52 Week High | $9.56 | $3.15 |
Technical Indicators
Market Signals| Indicator | PLCE | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 52.98 |
| Support Level | $2.86 | $1.48 |
| Resistance Level | $3.74 | $2.18 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 36.59 | 35.44 |
Price Performance
Historical ComparisonAbout PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.